Cargando…

A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice

BACKGROUND: Chikungunya virus (CHIKV) is a re-emerging arbovirus associated with febrile illness often accompanied by rash and arthralgia that may persist for several years. Outbreaks are associated with high morbidity and create a public health challenge for countries affected. Recent outbreaks hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weger-Lucarelli, James, Chu, Haiyan, Aliota, Matthew T., Partidos, Charalambos D., Osorio, Jorge E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109897/ https://www.ncbi.nlm.nih.gov/pubmed/25058320 http://dx.doi.org/10.1371/journal.pntd.0002970

Ejemplares similares

Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses
por: Weger-Lucarelli, James, et al.
Publicado: (2015)

Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism
por: Plante, Kenneth, et al.
Publicado: (2011)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
por: Ambuel, Yuping, et al.
Publicado: (2014)

Expression of anti-chikungunya single-domain antibodies in transgenic Aedes aegypti reduces vector competence for chikungunya virus and Mayaro virus
por: Webb, Emily M., et al.
Publicado: (2023)

Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice
por: Caine, Elizabeth A., et al.
Publicado: (2015)

Adaptation of Enterovirus 71 to Adult Interferon Deficient Mice
por: Caine, Elizabeth A., et al.
Publicado: (2013)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates
por: Strouts, Fiona R., et al.
Publicado: (2016)

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
por: Förster, Reinhold, et al.
Publicado: (2020)

Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection
por: Chen, Huixin, et al.
Publicado: (2020)

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
por: Reyes-Sandoval, Arturo, et al.
Publicado: (2012)

Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice
por: Gao, Feixia, et al.
Publicado: (2023)

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use
por: Wahren, Britta, et al.
Publicado: (2006)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
por: Alharbi, Naif Khalaf, et al.
Publicado: (2017)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

The wMel Strain of Wolbachia Reduces Transmission of Chikungunya Virus in Aedes aegypti
por: Aliota, Matthew T., et al.
Publicado: (2016)

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
por: Couto, Elvira, et al.
Publicado: (2019)

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
por: Nigam, Pragati, et al.
Publicado: (2007)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
por: López-Gil, Elena, et al.
Publicado: (2020)

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
por: Tscherne, Alina, et al.
Publicado: (2021)

Zika virus like particles elicit protective antibodies in mice
por: Salvo, Mauricio A., et al.
Publicado: (2018)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2023)

Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated In Vivo and Have Compromised Transmissibility
por: Carrau, Lucía, et al.
Publicado: (2019)

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates
por: Pierantoni, Angiolo, et al.
Publicado: (2015)

Infectious RNA vaccine protects mice against chikungunya virus infection
por: Szurgot, Inga, et al.
Publicado: (2020)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
por: Muthumani, Karuppiah, et al.
Publicado: (2016)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Chikungunya Virus–Vector Interactions
por: Coffey, Lark L., et al.
Publicado: (2014)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
por: Green, C, et al.
Publicado: (2023)

Chikungunya virus superinfection exclusion is mediated by a block in viral replication and does not rely on non-structural protein 2
por: Boussier, Jeremy, et al.
Publicado: (2020)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Immune Protective Evaluation Elicited by DNA Vaccination With Neospora caninum Dense Granules Proteins in Mice
por: Yu, Guili, et al.
Publicado: (2021)

Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses
por: Tao, Sha, et al.
Publicado: (2019)

MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease
por: Liu, Ruikang, et al.
Publicado: (2021)

A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease
por: Campos, Rafael Kroon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e310t0se5gfi6uvvgkmoij2spt